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Physiology ofthe ECL Cells
R. HMkansona, D. Chen, E. Lindstrom, P. Norlen,
M. Bjorkqvist and D. Lehto-Axtelius
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The enterochromaffin-like (ECL) cells of the oxyntic mucosa (fundus) of the
stomach produce, store andsecretehistamine, chromograninA-derivedpeptides
such aspancreastatin, andanunanticipated butasyetunidentifiedpeptidehormone.
The cells are stimulated by gastrin and pituitary adenylate cyclase activating
peptide and suppressedby somatostatin andgalanin. Choline esters andhistamine
seem to be without effect on ECLcell secretion. The existence ofagastrin-ECL
cell axis not only explains how gastrin stimulates acid secretion but also may
help to explore the functional significance of the ECL cells with respect to the
nature andbioactivity ofits peptidehormone. Fromtheresults ofstudies ofgas-
trectomized/fundectomized and gastrin-treated rats, it has been speculated that
the anticipated ECL-cell peptide hormone acts on bone metabolism.
INTRODUCTION
This review attempts to summarize what is known ofthe mechanisms thatcontrol the
activity of the enterochromaffin-like (ECL)b cells in the rat stomach and describes also
current speculations about their functional significance. Morphological aspects of the
ECL cells are discussed in another chapter in this volume [1]. The ECL cells are known
to produce, store and secrete histamine and chromogranin A (CGA)-derived peptides,
such as pancreastatin; in addition, they are suspected to manufacture an as yet unidentified
peptide hormone [2, 3]. The secretory products are stored in secretory vesicles, which
have a very characteristic ultrastructural appearance [1, 4-7]. The products appear to be
released in parallel in response to stimulation [7, 8]. The functional significance of the
ECL cells can be expected to reflect the nature and bioactivity ofthe secreted products.
ECL CELLS: OPERATIONAL CONTROL
In vivo studies
Much information on the mechanisms that control the activity of the ECL cells is
already available in the literature from decades of in vivo studies [2, 3]. It is generally
accepted that gastrin is a major stimulus for the ECLcells, causing secretory activation as
well as hypertrophy/hyperplasia. Secretory activation is manifested in the prompt mobi-
lization ofhistamine and pancreastatin and followed by activation ofthe histamine-forming
enzyme histidine decarboxylase (HDC). Ifthe gastrin stimulus is sustained for a long period
oftime the ECL cells will respond with hypertrophy and general, diffuse hyperplasia, and
ultimately with dysplasia (focal hyperplasia and micronodules) and neoplasia (frank
tumors) [9].
Although it seems to be generally accepted that the ECL cells operate under vagal
control the evidence for this view is not overwhelming. Gastrin and the vagus are thought
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to interact in an intricate manner in regulating various activities in the oxyntic mucosa
(e.g., ECL cell activation, parietal cell activation), and it is difficult to define the precise
contribution ofeach individual stimulus on each individual target. Frompublished reports
it appears that vagally denervated ECL cells respond poorly to the trophic action of gas-
trin [10-12]. It appears to be generally accepted that the vagus controls the ECL cells and
that acetylcholine is the neurotransmitter involved. In fact, however, the vagal control of
the ECL cells (and of all other epithelial cells in the oxyntic mucosa) is mediated by
enteric neurons (probably those in the myenteric plexus) [13], and the nature and identity
of the relevant transmitters are unknown.
The activity of the ECL cells can be suppressed by exogenously administered
somatostatin [14] and histamine [15, 16]. Somatostatin occurs in paracrine cells in the
oxyntic mucosa [14, 17] and is thought to modulate the activity ofthe ECL cells by way of
direct contact or per diffusionem. In the past, exogenous histamine has been found to be
quite effective in suppressing the HDC activity ofthe ECLcells [15]. In fact, histamine was
proposed to suppress the activity ofthe ECL cell by way of auto feedback inhibition; the
receptor involved was tentatively identified as ahistamine H2-receptor [16]. However, the
design ofthese experiments was such that indirect effects ofhistamine could not be excluded.
Table 1. Screening ofvarious regulatory peptides and neurotransmitters to demonstrate stim-
ulated secretion and suppression ofgastrin-induced secretion from isolated ECL cells.
Peptides Stimulation Suppression Peptides Stimulation Suppression
Gastrin ++++ - NMU +
Gastrin-Gly - - Substance P -
CCK-8s ++++ - Somatostatin - ++++
PACAP-27 ++++ - Met-enkephalin - -
PACAP-38 ++++ - Leu-enkephalin - -
VIP +++ - P-Endorphin - -
Helodermin + - Dynorphin - -
Helospectin II + - Pancreastatin - -
Glucagon
GLP-1 - Amino acids
GLP-2 - - Aspartate - -
Secretin + - GABA - -
GIP - - Glutamate - -
PTH - -
Calcitonin - - Amines, choline esters
CGRP - - Acetylcholine - -
GRP - - Bethanechol - -
Galanin - +++ Carbachol - -
NPY - - Histamine - -
pYy - - Serotonin + -
pp - - Dopamine + -
Bradykinin - - Noradrenaline ++ -
Motilin - - Adrenaline ++ -
Neurotensin + - Isoprenaline ++ -
Insulin
Each agent was tested on at least four separate isolated cell preparations, except in the case of
CGRP, NPY, PYY, PP, PACAP, choline esters and histamine. The latter agents were screened at least
10 times. Peptides were tested at a concentration 10-7 M. All other agents were screened at 10-4 M
concentration. Suppression was studied with cells stimulated with EC80 gastrin. ++++, potent and
powerful; +++, strong; ++, moderate; +, weak; -, no effect.
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Table 2. Stimulatory effect of gastrin, PACAP and VIP on secretion of histamine and pan-
creastatin from ECL cells.
EC50 Maximum EC50 Maximum
histamine secretion pancreastatin secretion
Peptide secretion (% increase) secretion (% increase)
Gastrin 6x 10-10M 320 2x 010 M 410
CCK-8 4x 010 M 310 2x 10-10M 390
PACAP-27 lOx 10o- M 310 6x 10-11 M 360
PACAP-38 9xl0o1M 300 3 x 10-11 M 380
VIP lOx 1010M 220 4x 10-10M 280
Mean values of 6-10 concentration response curves.
EC50, concentration ofpeptide that elicits 50% ofmaximum effect.
In vitro studies
The fairly recent development of a method for the preparation of isolated, near-pure
ECL cells by Prinz et al. [18, 19] will make it possible to demonstrate receptors and binding
sites on the ECL cells directly and to examine in detail the signal transduction mecha-
nisms that are activated by the different stimuli. We have accumulated data from studies
ofmore than 200 preparations ofisolated ECLcells with areproducible yield of2-3 x 106
ECL cells from five rat stomachs; the ECL cells constitute 80-90 percent of the cells in
the final preparation [8]. Anumber ofregulatory peptides and neurotransmitters were tested
for their ability to affect secretion from the ECL cells. A fairly limited number of the
agents tested were found to be active (Table 1). Briefly, gastrin causes a parallel release
of histamine and pancreastatin, and also the neuropeptides pituitary adenylate cyclase
activating peptide (PACAP) and vasoactive intestinal peptide (VIP) were able to stimulate
secretion. PACAPwas more potentthan gastrin, while VIPseemed to be less potent (Table
2). Of the regulatory peptides tested not only somatostatin but also galanin were able to
suppress gastrin-evoked (and PACAP-evoked) secretion (Table 2). Choline esters and the
amino acid transmitters tested were inactive, while catecholamines and5-hydroxytryptamine
were moderately active. Our results differ from previously published reports in several
instances. Thus, we failed to observe an inhibiting effect of histamine. We also failed to
find a stimulating effect of choline esters. Since acetylcholine was inactive, it is unlikely
that the vagal control ofthe ECL cells is cholinergic. Instead, the nervous control may be
exercised by enteric neurons that use PACAP (or possibly VIP) as the excitatory trans-
mitter and galanin as the inhibitory transmitter. Interestingly, the oxyntic mucosa is richly
supplied with nerve fibers that contain PACAP and/or VIP [13, 20-22]. Also galanin
occurs in nerve fibers in the oxyntic mucosa [23]. We conclude from ourdata that not only
gastrin but also PACAPis apowerful excitant ofthe ECLcells, that not only somatostatin
but also galanin can suppress secretion, that muscarinic receptor agonists fail to evoke
secretion, and that histamine (and pancreastatin) does not evoke auto feedback inhibition [8].





Figure 1. The percentage ofbone in rat calvaria at different times after gastrectomy or sham
operation. The analysis was performed by computer-assisted image analysis on decalcified sec-
tions. The bone surface area is expressed as percentage of the total biopsy surface. Mean values ±
SEM, 33-56 rats in each group. The number of rats examined at each point varied between 5 and








SHAM+NaCI SHAM+CaCI2 GX+NaCI GX+CaCI2
Figure 2. Morphometric analysis of sections of calvaria from rats subjected to: sham opera-
tion, SHAM and treatment with NaCI, (A); SHAM and treatment with CaCI , (B); gastrecto-
my, GX and treatment with NaCI, (C); and GX and treatment with Caad2, (D). Each rat
received 100 mg calcium chloride dihydrate or equivalent amount of sodium chloride by the oral
route daily for 7 weeks. The analysis was performed by computer-assisted image analysis ofdecal-
cified sections. *** p < .01; ANOVA, multiple comparisons, two-way analysis. Mean values ±
SEM; 8-10 rats in each group. NS, not significant. Data from Ref. [37].
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THE GASTRIN-ECL-CELLAXIS
The ECLcells operate under the control ofcirculating gastrin [2, 3]. The relationship
between gastrin and the ECLcells is so close that we have proposed the term gastrin-ECL
cell axis. The biological significance ofthe ECL cells is linked with the actions of locally
released histamine and the systemic actions ofthe anticipated ECL-cell peptide hormone.
ECL-cell histamine is mobilized by gastrin to stimulate the parietal cells [24, 25] and it
appears to be generally acceptedby now thatthe acid-stimulating effectofgastrin is medi-
ated by ECL-cell histamine. The evidence for this view is summarized in another chapter
of this book [26]. It may be pointed out here that ECL-cell histamine does not seem to
mediate vagus-stimulated acid secretion [25].
It is not unusual to see the ECL cells dismissed as representing merely the local
source ofgastric histamine necessary for the activation ofthe parietal cells. In fact, how-
ever, there is compelling evidence that the ECL cells produce not only histamine but also
a peptide hormone. The concomitant formation of an amine and a regulatory peptide is a
feature shared with a great many different peptide hormone-producing cell populations
[27]. Admittedly, the arguments in favor of the view that the ECL cells are the source of
a peptide hormone are indirect. First, the ECL cells share the properties of all other pep-
tide hormone-producing endocrine cells in the body (Table 3). Recently, they were found
to be supplied with the full range of exocytotic proteins associated with neurons and
endocrine cells [28]. In addition, observations documented in the literature make it possible
to speculate that the ECL cells are engaged in specific functions not related to histamine
(see below).
FUNCTIONAL SIGNIFICANCE OF THE ECL CELLS
Circulatingpancreastatin-a marker ofECL cell activity and number
The ECL cells constitute one of the largest endocrine cell populations in the body.
They are rich in CGA-derived peptides, such as pancreastatin [7, 29, 30]. The ECL cells
contain about 25 percent of the body's total content of pancreastatin and account for 75
percent of the circulating pancreastatin [31]. Furthermore, at least 90 percent of circulat-
ing pancreastatin in hypergastrinemic rats (omeprazole treatment) derive from the ECL
cells [32]. From these data it can be surmised that the ECL cell population represents a
quantitatively prominent endocrine organ. CGAand the CGA-derived peptides are gener-
ally thought to play a role in the packaging, processing and storage ofthe actual secretory
products rather than being messenger compounds in their own right [33]. It is possible,
Table 3. Characteristic features ofECLcells in oxyntic mucosa of rat stomach.
Properties in common with known peptide
hormone-producing cells Unique properties
Positive argyrophil staining Production, storage and secretion ofhistamine
Cytoplasmic (secretory) granules Responsiveness to gastrin
Exocytotic proteins
Chromogranins in the granules
Proteolytic "processing" enzymes in the granules
APUD properties*
Co-storage ofamines and peptides in granules*
*For a discussion ofthese features see Sundler et al. (1980).
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even likely, that the formation, packaging, processing and secretion of the anticipated
ECL-cell hormone occurs in parallel with CGA and that what we learn about the manu-
facture and handling ofCGAin the ECLcells will help us understand the mechanisms that
control the manufacture and handling of the ECL-cell peptide hormone.
Anticipated ECL-cellpeptide hormone
We have speculated in the past that the key role of the ECL cells is associated with
the anticipated peptide hormone rather than with histamine. In endocrinology, a classical
approach to detect unknown but anticipated hormonal principles is to examine the conse-
quences ofresection ofthe organ under suspicion. Resection ofthe stomach is known to be
associated with osteopathy. This was first demonstrated in young dogs and monkeys by Ivy
and co-workers [34, 35]. It was generally assumed at the time that the osteopathy reflect-
ed nutritional deficiency. Since then numerous observations both in the clinical setting and
in experimental animals have confirmed the importance ofthe stomach for skeletal health.
As expected, gastrectomy causes the development of osteopathy in the rat [36-40].
This was manifested in all bones examined, most dramatically in the calvaria [37]. Also,
trabecules were lost to a great extent [36]. The effect was near-maximal within 8-12 weeks
(Figure 1). There are several possible explanations for the gastrectomy-evoked osteopathy.
First, general nutritional deficiency may be responsible. However, the food intake
appeared normal and the curve illustrating the body weight development was not much
affected by the surgery. Hence, it is unlikely that a general nutritional deficiency accounts
for the gastrectomy-evoked bone loss. Also, calcium supplementation by the peroral or
systemic route failed to prevent the gastrectomy-evoked osteopathy [36, 37] (Figure 2).
At present, we have no evidence that vitamin D deficiency contributes to the gastrectomy-
evoked osteopathy [41]. Circulating concentrations of Ca+2, PTH and calcitonin were
unaffected by gastrectomy (HAkanson et al., to be published). Hence it is unlikely that
hyperparathyroidism is responsible for the gastrectomy-evoked bone loss. Lack ofgastric
acid, as after treatment with the proton pump inhibitor omeprazole, did not induce
osteopathy [36]. It appears therefore that the gastrectomy-evoked bone loss is a conse-
quence of the loss of the stomach per se and that the stomach plays an as yet unidentified
role in controlling bone status. In another series of experiments we tried to establish
whether defined parts of the stomach were as important to bone metabolism as was the
whole stomach [39]. Removal of the acid-producing part of the stomach (fundectomy)
resulted in the same degree of osteopathy as did gastrectomy, whereas antrectomy had
only little effect. We conclude that while fundectomy completely reproduces the effects of
gastrectomy, antrectomy has little effect. We speculate therefore that the bone loss
observed after gastrectomy reflects the loss oftheoxyntic mucosa and ofacirculating hor-
mone originating in one ofthe endocrine cell populations in this location.
Schulak and Kaplan [42, 43] and Kaplan et al. [44] reported that gastrin evokes tran-
sient hypocalcemia in the rat. This effect was unaffected by thyroparathyroidectomy but
abolishedby gastrectomy orfundectomy. We were able to confirm these observations with
respect not only to exogenous but also to endogenous gastrin [45-47]. In addition, we
demonstrated that gastrin-free extracts ofthe oxyntic mucosa mimicked the effect ofgastrin
on blood calcium. The gastrin-induced hypocalcemia reflected the stimulated uptake of
45Ca2+ into bone. We suggest that gastrin causes hypocalcemia by releasing a blood cal-
cium-lowering hormone from the acid-producing part of the stomach and speculated that
the oxyntic mucosa contains a hormone (gastrocalcin), which is released in response to
gastrin (which in turn is released in response to food intake) [48]. The ECL cells are like-
ly candidates for such a hormone because they operate under the control ofgastrin.
If the ECL cells secrete a calciotropic hormone it is to be expected that they should
respond to perturbations in the concentration of blood Ca2+. While changes in the blood
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Ca2+ concentration induced the expected changes in the circulating concentrations ofcal-
citonin and PTH, the ECL cells failed to respond [49]. We conclude that the ECL cells do
not secrete a calciotrophic hormone. It cannot be excluded, however, that they produce a
hormone with a primary action on bone rather than on Ca2+
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